SOURCE: Hemostemix Inc.

April 20, 2015 09:03 ET

Hemostemix to Present at the 2015 Annual Meeting of the Clinical Trials Association in Israel

CALGARY, AB--(Marketwired - Apr 20, 2015) - Hemostemix Inc. (the "Corporation") (TSX VENTURE: HEM), a clinical-stage autologous cell-therapy company, announced today that its President and CEO, Dr. Elmar Burchardt, will present on clinical-trial strategies for critical limb ischemia (CLI) at the Annual Meeting of the Clinical Trials Association in Israel on April 28, 2015, at the David Intercontinental Hotel in Tel Aviv.

Dr. Burchardt's presentation from 3:40-4:00 p.m. (IDT) is entitled "Autologous Cell Therapy, Clinical Development of an Autologous Cell Therapy for Critical Limb Ischemia: Building on Past Successes and Lessons Learned."

Hemostemix is the first clinical-stage biotech company to test a potential breakthrough stem-cell therapy in an international, multicenter, phase-2 clinical trial for patients with CLI, a severe form of peripheral artery disease (PAD) caused by reduced blood flow to the legs. About half of CLI patients either die or require amputation of the affected limb within one year of diagnosis. Demand for a treatment is on the rise, as CLI predominately affects the growing population aged 50 and older.

The phase-2 trial targets a participant's diseased tissue with proprietary cells that are grown from his or her blood and capable of supporting the formation of new blood vessels. Hemostemix currently enrolls participants in the phase-2 trial at four sites in South Africa and two sites in Canada.

Hemostemix operates a research, development, and manufacturing facility in Kiryat Weizmann Science Park, Ness Ziona, Israel.

About Hemostemix
Hemostemix is a public clinical-stage biotechnology company that develops and commercializes innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments. Hemostemix Inc. is traded on the TSX Venture Exchange under the trading symbol HEM. For more information, visit hemostemix.com or email office@hemostemix.com.

About the Conference
For more information on the Annual Meeting of the Clinical Trials Association in Israel, visit bioforumconf.com/english.

Neither the TSX Venture Exchange, Inc. nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," and similar expressions, or that events or conditions "will," "would," "may," "could," or "should" occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Hemostemix management on the date such statements were made. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Contact Information

  • Contacts

    Hemostemix Inc.
    Dr. Elmar Burchardt
    President and CEO
    Phone: (617) 500-8401

    C.W. (Bill) Baker
    Chairman of the Board
    Phone: (403) 818-7672